Growth hormone's receptor controls growth, metabolism, and cancer risk
The growth hormone receptor is the key molecular switch that controls postnatal growth, skeletal development, and metabolism through several cellular signaling pathways. People with lifelong growth hormone receptor deficiency show short stature but also enhanced insulin sensitivity and very low cancer rates.
Why it matters: Understanding how growth hormone signaling affects aging and cancer may reveal new therapeutic targets for metabolic and cancer control.
Keep in mind: This is an overview article that synthesizes existing knowledge and does not present new experimental results or clinical trial data.
AI-assisted explanation based on the supplied abstract. Read the linked source for full context.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 4, 2026 · Discovered: Sep 14, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Systematic review
- Sample size
- —
- Duration
- —
- Population
- General review of growth hormone-IGF axis physiology, with specific reference to patients with Laron syndrome (GHR deficiency) from an Ecuadorian cohort
- Primary outcome
- Physiological roles of the GH-IGF axis in growth, metabolism, and disease (cancer)
- Effect size
- —
- Significance
- Not reported
- Journal
- Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
- Published
- Sep 4, 2026
Sources
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.